

Harriet Johansson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4373830/publications.pdf>

Version: 2024-02-01

50
papers

2,100
citations

304743

22
h-index

233421

45
g-index

50
all docs

50
docs citations

50
times ranked

3066
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519.	1.6	3
2	Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. <i>Clinical Cancer Research</i> , 2021, 27, 3576-3583.	7.0	10
3	Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: Comprehensive meta-analysis of all cancer sites. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103202.	4.4	14
4	Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. <i>Npj Breast Cancer</i> , 2021, 7, 34.	5.2	5
5	Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort. <i>Nutrients</i> , 2021, 13, 1208.	4.1	6
6	Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial. <i>Nutrients</i> , 2021, 13, 1931.	4.1	20
7	A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. <i>Cancers</i> , 2021, 13, 3303.	3.7	8
8	An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. <i>Clinical Epigenetics</i> , 2021, 13, 224.	4.1	7
9	Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 19-26.	2.0	8
10	First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. <i>ESMO Open</i> , 2020, 5, e000859.	4.5	6
11	Development of an HPLC-MS/MS Method for the Determination of Silybin in Human Plasma, Urine and Breast Tissue. <i>Molecules</i> , 2020, 25, 2918.	3.8	1
12	Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa096.	2.9	3
13	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	1.6	16
14	Quality of Life in a Randomized Breast Cancer Prevention Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women. <i>Cancer Prevention Research</i> , 2018, 11, 811-818.	1.5	6
15	A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 363-370.	1.5	56
16	Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 437-444.	1.5	19
17	A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 97-108.	2.5	10
18	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016, 18, 110.	5.0	22

#	ARTICLE	IF	CITATIONS
19	A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. <i>Cancer Prevention Research</i> , 2016, 9, 349-356.	1.5	14
20	Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients. <i>International Journal of Cancer</i> , 2016, 138, 237-244.	5.1	34
21	A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 89-95.	1.5	35
22	RE: Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. <i>Journal of the National Cancer Institute</i> , 2015, 108, djw014.	6.3	1
23	Telomere length and the risk of cutaneous melanoma and non-melanoma skin cancer: a review of the literature and meta-analysis. <i>Journal of Dermatological Science</i> , 2015, 80, 168-174.	1.9	42
24	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 321-329.	2.5	7
25	Metabolic syndrome and breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 159-165.	2.5	114
26	Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 569-578.	2.5	20
27	A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R47.	5.0	23
28	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2600.	1.6	218
29	Prognostic Effect of Circulating Adiponectin in a Randomized 2 Å– 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 151-157.	1.6	63
30	Lapatinib Activity in Premalignant Lesions and HER-2â€™Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. <i>Cancer Prevention Research</i> , 2011, 4, 1181-1189.	1.5	52
31	Abstract A56: Randomized, placebo-controlled, phase III trial of low-dose tamoxifen in women with intraepithelial neoplasia. , 2011, , .		6
32	Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. <i>Clinical Cancer Research</i> , 2009, 15, 7053-7060.	7.0	21
33	Randomized Double-Blind 2 Å– 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2009, 27, 3749-3756.	1.6	98
34	Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. <i>Carcinogenesis</i> , 2009, 30, 1170-1180.	2.8	229
35	Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 57-67.	2.5	59
36	Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer. <i>Cancer Research</i> , 2008, 68, 9512-9518.	0.9	72

#	ARTICLE	IF	CITATIONS
37	Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users. <i>Journal of Clinical Oncology</i> , 2007, 25, 4201-4209.	1.6	64
38	Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 263-271.	2.5	55
39	Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 167-172.	2.5	7
40	Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 Å– 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2006, 24, 129-135.	1.6	40
41	Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2083-2088.	7.0	6
42	A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers. <i>Clinical Cancer Research</i> , 2004, 10, 4389-4397.	7.0	26
43	Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 88, 63-73.	2.5	25
44	A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 779-790.	6.3	190
45	Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. <i>Clinical Cancer Research</i> , 2003, 9, 4722-9.	7.0	21
46	Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women. <i>Circulation</i> , 2002, 106, 1224-1228.	1.6	112
47	Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. <i>Breast Cancer Research and Treatment</i> , 2001, 69, 21-27.	2.5	34
48	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. <i>International Journal of Cancer</i> , 2000, 87, 601-605.	5.1	20
49	Effect of Blood Tamoxifen Concentrations on Surrogate Biomarkers in a Trial of Dose Reduction in Healthy Women. <i>Journal of Clinical Oncology</i> , 1999, 17, 2633-2633.	1.6	74
50	Biologic Activity of Tamoxifen at Low Doses in Healthy Women. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1461-1467.	6.3	98